Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 3, 2005, Pages 1274-1289

  Schechter, L E ^a,h   Smith, D L ^a   Rosenzweig Lipson, S ^a   Sukoff, S J ^a   Dawson, L A ^a,e   Marquis, K ^a   Jones, D ^a   Piesla, M ^a   Andree, T ^a   Nawoschik, S ^a   Harder, J A ^b   Womack, M D ^b   Buccafusco, J ^c   Terry, A V ^c   Hoebel, B ^d   Rada, P ^d   Kelly, M ^a,f   Abou Gharbia, M ^a   Barrett, J E ^a,g   Childers, W ^a  

^a Chemical and Screening Sciences   (United States)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d PRINCETON UNIVERSITY   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f EVOTEC AG   (Germany)

^g ADOLOR CORPORATION   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ACETYLCHOLINE; DIZOCILPINE; GLUTAMIC ACID; LECOZOTAN; NOOTROPIC AGENT; POTASSIUM CHLORIDE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSOCIATION; BEHAVIOR; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DENTATE GYRUS; DRUG BINDING; DRUG DETERMINATION; DRUG DISCRIMINATION; DRUG TOLERANCE; FEMALE; HIPPOCAMPUS; LEARNING DISORDER; MALE; MARMOSET; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; PERCEPTION; PIGEON; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SPATIAL DISCRIMINATION; TASK PERFORMANCE; VISUAL STIMULATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; CALLITHRIX; COGNITION; COLUMBIDAE; DIOXANES; DISCRIMINATION LEARNING; FEMALE; GANGLIA, SPINAL; GLUTAMIC ACID; HIPPOCAMPUS; MACACA MULATTA; MALE; METHOXYDIMETHYLTRYPTAMINES; MICRODIALYSIS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SAIMIRI; SEROTONIN ANTAGONISTS;

EID: 23944507839     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.086363     Document Type: Article

References (56)

1. Araneda R and Andrade R (1991) 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40:399-412.
2. Arvidsson LE, Hacksell U, Nilsson JL, Hjorth S, Carlsson A, Lindberg P, Sanchez D, and Wikstrom H (1981) 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem 24:921-923.
3. 1A receptor antagonist WAY 100635. Psychopharmacology 167:28-36.
4. Bartus R (2000) On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neur 163:495-529.
5. Bliss TV and Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature (Lond) 361:31-39.
6. Boast C, Bartolomeo AC, Morris H, and Moyer JA (1999) 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. Neurobiol Learn Mem 71:259-271.
7. Bowen DM, Francis PT, Chessell IP, and Webster MT (1994) Neurotransmission-the link integrating Alzheimer research? Trends Neurosci 17:149-150.
8. Braak H and Braak E (1991) Alzheimer's disease affects limbic nuclei of the thalamus. Acta Neuropathol 82:239-259.
9. Buccafusco JJ and Terry AV Jr (2000) Multiple CNS targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 295:438-446.
10. Chanda PK, Minchin MC, Davis AR, Greenberg L, Reilly Y, McGregor WH, Bhat R, Lubeck MD, Mizutani S, and Hung PP (1993) Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. Mol Pharmacol 43:516-520.
11. Czyrak A, Czepiel K, Maćkowiak M, Chocyk A, and Wçdzony K (2003) Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulated cortex. Brain Res 989:42-51.
12. Dawson LA and Routledge C (1995) Differential effects of potassium channel blockers on extracellular concentrations of dopamine and 5-HT in the striatum of conscious rats. Br J Pharmacol 116:3260-3264.
13. Dawson LA, Stow JM, and Palmer AM (1997) An improved method for the measurement of glutamate and aspartate using capillary electrophoresis with laser induced fluorescence detection and its application to brain microdialysis. J Chromatogr B 694:455-460.
14. 1A antagonist. Br J Pharmacol 115:1169-1174.
15. Eichenbaum H, Otto T, and Cohen EJ (1992) The hippocampus - what does it do? Behav Neural Biol 57:2-36.
16. 1A receptor. Nature (Lond) 335:358-360.
17. 1A receptors. Eur J Pharmacol 237:283-291.
18. Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJ, et al. (1996) Electrophysiological, biochemical, neurohormonal and behavioral studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73:337-353.
19. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, and Fletcher A (1995) A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81-88.
20. Francis PT, Sims NR, Proctor AW, and Bowen DM (1993) Cortical pyramidal neuron loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease. J Neurochem 60:1589-1604.
21. 3H-PAT. Nature (Lond) 305:140-142.
22. Greuel JM and Glaser T (1992) The putative 5-HT1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro. Eur J Pharmacol 211:211-219.
23. Grunschlag CR, Haas HL, and Stevens DR (1997) 5-HT inhibits lateral entorhinal cortical neurons of the rat in vitro by activation of potassium channel-coupled 5-HT1A receptors. Brain Res 770:10-17.
24. Harder JA, Baker HF, and Ridley RM (1998) The role of the central cholinergic projections in cognition: implications of the effects of scopolamine on discrimination learning by monkeys. Brain Res Bull 45:319-326.
25. 1A antagonist, WAY-100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology 127:245-254.
26. 1A antagonist, WAY-100635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 39:547-552.
27. Hernandez L, Tucci S, Gusman N, and Paez X (1993) In vivo monitoring of glutamate in the brain by microdialysis and capillary electrophoresis with laser-induced fluorescence detection. J Chromatogr A 652:393-398.
28. Jarrard LE (1993) On the role of the hippocampus in learning and memory in the rat. Behav Neural Biol 60:9-26.
29. 1A receptor antagonist, NAD-299. J Pharmacol Exp Ther 283:216-225.
30. Kelleher RT, Morse WH, and Herd JA (1972) Effects of propranolol, phentolamine and methyl atropine on cardiovascular function in the squirrel monkey during behavioral experiments. J Pharmacol Exp Ther 182:204-217.
31. Kowall NW and Beal MF (1991) Glutamate-, glutaminase- and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Ann Neurol 29:162-167.
32. 35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies. Br J Pharmacol 109:1120-1127.
33. Lowry OH, Rosenbrough NJ, Farr AL, and Randall RJ (1951) Protein measurements with folin phenol reagent. J Biol Chem 193:265-275.
34. Maragos WF, Greenamyre T, Penney JB Jr, and Young AB (1987) Glutamate dysfunction in Alzheimer's disease: a hypothesis. Trends Neurosci 10:65-67.
35. Matsuyama S, Nei K, and Tanaka C (1996) Regulation of glutamate release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus. Brain Res 728:175-180.
36. McLoughlin DM, Lucey JV, and Dinan G (1994) Central serotonergic hyperresponsivity in late-onset Alzheimer's disease. Am J Psychiatry 151:1701-1703.
37. Morris RG, Anderson E, Lynch GS, and Baudry M (1986) Selective impairment of learning and blockade of long term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature (Lond) 319:774-776.
38. Myhrer T (1993) Animal models of Alzheimer's Disease: glutamatergic denervations an alternative approach to cholinergic denervation. Neurosci Behav Rev 17:195-202.
39. Paule MG, Bushnell PJ, Maurissen JPJ, Wenger GR, Buccafusco JJ, Chelonis JJ, and Elliott R (1998) Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol Teratol 20:493-502.
40. Paxinos G, Watson C, Pennisi M, and Topple A (1985) Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Meth 13:139-143.
41. 3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36:220-226.
42. 1A receptor antagonist WAY 100635 improves rat's performance in different models of amnesia evaluated by the object recognition task. Brain Res 983:215-222.
43. Proctor AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, Doshi R, and Bowen DM (1988) Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's Disease. J Neurochem 50:790-802.
44. Rada P, Jensen K, and Hoebel BG (2001) Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. Psychopharmacology 157:105-110.
45. 1A antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. J Pharmacol Exp Ther 294:688-700.
46. Ridley RM and Baker HF (1991) A critical evaluation of monkey models of amnesia and dementia. Brain Res Rev 16:15-37.
47. Ridley RM, Barefoot HC, Maclean CJ, Pugh P, and Baker HF (1999) Severe learning impairment caused by combined immunotoxic lesion of the cholinergic projections to the cortex and hippocampus in monkeys. Brain Res 836:120-138.
48. Santucci AC and Shaw C (2003) Peripheral 8-OH-DPAT and scopolamine infused into the frontal cortex produce passive avoidance retention impairments in rats. Neurobiol Learn Mem 79:136-141.
49. 1A receptor antagonist. Soc Neurosci 26:392.
50. Schmitz D, Empson RM, and Heinemann U (1995) Serotonin and 8-OH-DPAT reduced excitatory transmission in rat hippocampal area CA1 via reduction in presumed presynaptic Ca2+ entry. Brain Res 701:249-254.
51. Smith LM and Peroutka SJ (1986) Differential effects of 5-hydroxytryptamine 1A selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 24:1513-1519.
52. 2+- and glutamatergic receptor-evoked arachidonic acid and NO/cGMP release in adult hippocampus. Neurochemistry 28:439-444.
53. Van den Hooff P and Galvan M (1991) Electrophysiology of the 5-HT1A ligand MDL 73005EF in the rat hippocampal slice. Eur J Pharmacol 196:291-298.
54. Van den Hooff P and Galvan M (1992) Actions of 5-hydroxytryptamine and 5-HT1A receptor ligands on rat dorso-lateral septal neurons in vitro. Br J Pharmacol 106:893-899.
55. Winsauer PJ, Rodriguez FH, Cha AE, and Moerschbaecher JM (1999) Full and partial 5-HT1A receptor agonists disrupt learning and performance in rats. J Pharmacol Exp Ther 288:335-347.
56. Yocca FD (1990) Novel anxiolytic agents: actions on specific subtypes of central 5-HT receptors. Prog Clin Biol Res 361:145-177.